Therefore, the application value of combining real-time USE with serum HE4, IL-33, and CA153 in diagnosing early cervical cancer was explored herein, in the hope of providing reference for establishing clinical treatment scheme and patient condition evaluation. This evidence concerns the gene IL33 and cervical cancer.